Novel Immunological Aspects of Sirolimus as a New Targeted Therapy for COVID-19
Abstract
No Abstract No Abstract No Abstract No Abstract
1. Rele S. Emerging outbreaks and epidemic threats: The practicality and limitations in the development and manufacturing of treatments for coronavirus (covid-19). Polymorphism 2020;4:45-52.
2. McIntosh K, McQuillin J, Reed SE, Gardner PS. Diagnosis of human coronavirus infection by immunofluorescence: Method and application to respiratory disease in hospitalized children. J Med Virol 1978;2(4):341-6.
3. O'Keefe BR, Giomarelli B, Barnard DL, et al. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family coronaviridae. J Virol 2010;84(5):2511-21.
4. Omarjee L, Janin A, Perrot F, Laviolle B, Meilhac O, Mahe G. Targeting t-cell senescence and cytokine storm with rapamycin to prevent severe progression in covid-19. Clin Immunol 2020.
5. Zhavoronkov A. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections. Aging (Albany NY) 2020;12(8):6492.
6. Abdel-Magid AF. Rapalogs potential as practical alternatives to rapamycin. ACS Publications; 2019.
7. Fagone P, Ciurleo R, Lombardo SD, et al. Transcriptional landscape of sars-cov-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies. Autoimmun Rev 2020:102571.
8. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-ncov/sars-cov-2. Cell Discov 2020;6(1):1-18.
9. Sargiacomo C, Sotgia F, Lisanti MP. Covid-19 and chronological aging: Senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging (Albany NY) 2020;12(8):6511.
10. Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for covid-19 are urgently needed. Lancet 2020;395(10234):1407-9.
11. Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses sars‐cov, mers‐cov, and 2019‐ncov. J Med Virol 2020;92(5):491-4.
12. Wang C-H, Chung F-T, Lin S-M, et al. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe h1n1 pneumonia and acute respiratory failure. Crit Care Med 2014;42(2):313-21.
2. McIntosh K, McQuillin J, Reed SE, Gardner PS. Diagnosis of human coronavirus infection by immunofluorescence: Method and application to respiratory disease in hospitalized children. J Med Virol 1978;2(4):341-6.
3. O'Keefe BR, Giomarelli B, Barnard DL, et al. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family coronaviridae. J Virol 2010;84(5):2511-21.
4. Omarjee L, Janin A, Perrot F, Laviolle B, Meilhac O, Mahe G. Targeting t-cell senescence and cytokine storm with rapamycin to prevent severe progression in covid-19. Clin Immunol 2020.
5. Zhavoronkov A. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections. Aging (Albany NY) 2020;12(8):6492.
6. Abdel-Magid AF. Rapalogs potential as practical alternatives to rapamycin. ACS Publications; 2019.
7. Fagone P, Ciurleo R, Lombardo SD, et al. Transcriptional landscape of sars-cov-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies. Autoimmun Rev 2020:102571.
8. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-ncov/sars-cov-2. Cell Discov 2020;6(1):1-18.
9. Sargiacomo C, Sotgia F, Lisanti MP. Covid-19 and chronological aging: Senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging (Albany NY) 2020;12(8):6511.
10. Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for covid-19 are urgently needed. Lancet 2020;395(10234):1407-9.
11. Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses sars‐cov, mers‐cov, and 2019‐ncov. J Med Virol 2020;92(5):491-4.
12. Wang C-H, Chung F-T, Lin S-M, et al. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe h1n1 pneumonia and acute respiratory failure. Crit Care Med 2014;42(2):313-21.
| Files | ||
| Issue | Vol 8, No 3 (Summer 2020) | |
| Section | Focus | |
| DOI | https://doi.org/10.18502/jpc.v8i3.4553 | |
| Keywords | ||
| NA | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Naserifar M, Hosseinjani H. Novel Immunological Aspects of Sirolimus as a New Targeted Therapy for COVID-19. J Pharm Care. 2020;8(3):152-153.
